Showing 7071-7080 of 9760 results for "".
- Cassiopea Enrolls First Patient in Phase II Trial of Clascoterone Solution for the Treatment of Androgenetic Alopecia in Femaleshttps://practicaldermatology.com/news/cassiopea-enrolls-first-patient-in-phase-ii-trial-of-clascoterone-solution-for-the-treatment-of-androgenetic-alopecia-in-females/2460215/After receiving approval from the German Authority BfArM and the coordinating ethical committee, Cassiopea SpA is now enrolling the first patient in a Phase II trial investigating clascoterone solution for the treatment of androgenetic alopecia (AGA) in fema
- Psoriasis Onset Determines if Psoriatic Arthritis Patients Develop Arthritis or Psoriasis Firsthttps://practicaldermatology.com/news/psoriasis-onset-determines-if-psoriatic-arthritis-patients-develop-arthritis-or-psoriasis-first/2460212/Age of psoriasis onset determines whether arthritis or psoriasis starts first in people with psoriatic arthritis., finds a new study presented at the 2019 ACR/ARP Annual Meeting in Atlanta. Additionally, pustular psoriasis is associated with arthritis onset two years earlier than the in
- Poll: People Who Developed AD Symptoms as Kids Experience More Severe Symptomshttps://practicaldermatology.com/news/poll-people-who-developed-ad-symptoms-as-kids-experience-more-severe-symptoms/2460206/Individuals who begin experiencing atopic dermatitis (AD) symptoms as children have vastly different patient journeys and experiences than those who began experiencing symptoms as adults, a new survey from Health Union suggests. Of the survey's 400 respondents, there was a nearly 50
- New AAD/NPF Guidelines Address Care for Pediatric Psoriasishttps://practicaldermatology.com/news/new-aadnpf-guidelines-address-care-for-pediatric-psoriasis/2460204/New guidelines from the American Academy of Dermatology and the National Psoriasis Foundation offer counsel on how to best manage psoriasis and its extracutaneous manifestations in children and adolescents. The
- Phase 3 Study: Aclaris Therapeutics’ A-101 45% May Help Thwart Common Wartshttps://practicaldermatology.com/news/phase-3-study-aclaris-therapeutics-a-101-45-may-help-thwart-common-warts/2460198/Aclaris Therapeutics, Inc.’s A-101 45% Topical Solution (A-101 45%), an investigational new drug, for the potential treatment of common warts, performed well in its second Phase 3 clinical trial, THWART-1 (WART-301). A-101 45% met the primary and all secondary efficacy endpoints,
- Arcutis Biotherapeutics Plans to Initiate Phase 3 Program for ARQ-151 for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-biotherapeutics-plans-to-initiate-phase-3-program-for-arq-151-for-plaque-psoriasis/2460196/Arcutis Biotherapeutics, Inc. plans to initiate its Phase 3 program of ARQ-151 as a potential topical treatment for plaque psoriasis following its End-of-Phase 2 meeting with the FDA. The Company anticipates initiating a Phase 3 clinical trial in the first half of 2020. Frank Watanabe,
- Consumers Cite Dermatologists as Top Influencers of Cosmetic Procedure, Skin Care Choices: ASDShttps://practicaldermatology.com/news/consumers-site-dermatologists-as-top-influencers-of-cosmetic-procedure-skin-care-choices-asds/2460191/When it comes to consumer decisions on cosmetic procedures and skin care choices, dermatologists are the leading influencers, results of the 2019
- Psoriasis Linked to Developing and Dying from Cancerhttps://practicaldermatology.com/news/psoriasis-linked-to-developing-and-dying-from-cancer/2460185/Psoriasis may increase the risk for certain cancers, according to a review of 58 studies published in JAMA Dermatology. Moreover, the risk of dying from certain site-specific cancers was elevated in those with severe psoriasis. Specifically, severe psoriasi
- Allergan Shareholders Approve Proposed Acquisition by AbbViehttps://practicaldermatology.com/news/allergan-shareholders-approve-proposed-acquisition-by-abbvie/2460181/Allergan’s shareholders approved the previously announced proposed acquisition of Allergan by AbbVie Inc. More than 99 percent of the votes cast at both a special court-ordered meeting of shareholders and at an extraordinary general meeting of shareholders were in favor of the tra
- Pediatric AD Takes Its Toll on Caregiver Emotional Wellbeinghttps://practicaldermatology.com/news/ad-takes-its-toll-on-caregiver-emotional-wellbeing/2460173/Family members and caregivers of children with atopic dermatitis (AD) may be at increased risk for anxiety and depression, according to new research presented at the 28th European Dermato-Venereology Society Congress in Madrid. Researchers from the PHIUniversity Clinic of Dermatol